Genotype, distribution and allele frequency of the two polymorphisms are shown in Table 2, and the main results of this meta-analysis are presented in Table 3. For LEP G2548A polymorphism, eight eligible studies with 2,124 BC patients and 2,089 cancer-free controls were finally identified. In general, we did not observe statistically significant association between LEP G2548A polymorphism and BC risk under the genetic models of AA versus GG, GA versus GG, AA+GA versus GG, AA versus GA+GG and G-allele versus A-allele (OR = 1.105 with 95 % CI 0.699-1.749, OR = 0.991 with 95 % CI 0.857-1.147, OR = 1.081 with 95 % CI 0.942-1.241, OR = 1.074 with 95 % CI 0.692-1.668 and OR = 1.02 with 95 % CI 0.792-1.134, respectively). In subgroup analysis by sources of controls, we also found no significant association between LEP G2548A polymorphism and the risk of BC among these five genetic models. Similarly, further stratified analysis by ethnicity showed no significant correlation between LEP G2548A polymorphism and BC susceptibility in all the ethnic groups (Table 3) (Figure 2).